glp 1 oral novo nordisk launched an version of its GLP-1 injectable to US markets on Jan 5. Link in comments Novo Nordisk justifies reasoning behind
Description
In a recent trial, semaglutide led to a 20% reduction in major adverse cardiovascular events (MACE) in patients []
Doing everything right and not seeing results
We aimed to e...
Companies operating in this space may benefit from reviewing their promotional materials to ensure alignment with FDA expectations
It dissolves easily in waterand fits easily into your life.
Coronary artery disease (CAD)cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteriesis responsible for disa...
